Insider tradingForm 4
OCULAR THERAPEUTIX, INC (OCUL) Insider Trading
8 open-market trades reported since Aug 26, 2026: 0 purchases worth $0 and 8 sales worth $568K.
By insider
| Insider | Role | Buys | Bought | Sells | Sold |
|---|---|---|---|---|---|
| Todd Anderman | General Counsel | 0 | $0 | 1 | $87K |
| Jeffrey S. Heier | Chief Scientific Officer | 0 | $0 | 2 | $112K |
| Peter Kaiser | Chief Development Officer | 0 | $0 | 2 | $103K |
| Donald Notman | COO | 0 | $0 | 1 | $11K |
| Pravin Dugel | See Remarks | 0 | $0 | 1 | $233K |
| Sanjay Nayak | Chief Strategy Officer | 0 | $0 | 1 | $20K |
ADVERTISEMENT
320 × 100 ad slot
All trades
| Filed | Insider | Type | Value | 3 mo. after |
|---|---|---|---|---|
| Oct 13 | Todd AndermanGeneral Counsel | ▼ SELL10b5-1 | $87K | |
| Oct 6 | Jeffrey S. HeierChief Scientific Officer | ▼ SELL10b5-1 | $77K | |
| Oct 6 | Peter KaiserChief Development Officer | ▼ SELL10b5-1 | $70K | |
| Sep 2 | Donald NotmanCOO | ▼ SELL | $11K | |
| Aug 26 | Pravin DugelSee Remarks | ▼ SELL10b5-1 | $233K | |
| Aug 26 | Jeffrey S. HeierChief Scientific Officer | ▼ SELL10b5-1 | $36K | |
| Aug 26 | Peter KaiserChief Development Officer | ▼ SELL10b5-1 | $33K | |
| Aug 26 | Sanjay NayakChief Strategy Officer | ▼ SELL10b5-1 | $20K |
Source: SEC Form 4 filings, retrieved Oct 28, 2026. How we read filings